Krebs von den Lungen 6 decreased in the serum and muscle of GNE myopathy patients.

Neuropathology

Department of Clinical Neuroscience and Therapeutics, Division of Applied Life Science, Hiroshima University Institute of Biomedical and Health Sciences, Hiroshima, Japan.

Published: February 2021

UDP-N-acetylglucosamine 2-epimerase/N-acetylmannosamine kinase (GNE) is necessary for sialic acid biosynthesis. GNE myopathy is caused by a defect in GNE, and hyposialylation is a key factor in the pathomechanism of GNE myopathy. Although candidates for evaluating hyposialylation have been reported, it is difficult to measure them in routine clinical practice. Sialylation is necessary for synthesis of various glycoproteins, including Krebs von den Lungen-6 (KL-6)/mucin 1 (MUC1). Here we report that KL-6/MUC1 is decreased in GNE myopathy. We observed that KL-6 levels were decreased in the serum of patients with GNE myopathy, and that KL-6 and MUC1-C were also decreased in muscle biopsy specimens from these patients. An immunofluorescent study revealed that KL-6 and MUC1-C were not present in the sarcolemma but were, instead, localized in rimmed vacuoles in specimens from patients with GNE myopathy. KL-6 is already used to detect lung diseases in clinical practice, and this glycoprotein may be a novel candidate for evaluating hyposialylation in GNE myopathy.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7983952PMC
http://dx.doi.org/10.1111/neup.12703DOI Listing

Publication Analysis

Top Keywords

gne myopathy
28
gne
9
krebs von
8
von den
8
decreased serum
8
evaluating hyposialylation
8
clinical practice
8
patients gne
8
myopathy kl-6
8
kl-6 muc1-c
8

Similar Publications

Clinical features, mutation spectrum and factors related to reaching molecular diagnosis in a cohort of patients with distal myopathies.

J Neurol

January 2025

Neuromuscular Diseases Unit, Neurology Department, Hospital Universitari I Politècnic La Fe, Neuromuscular Reference Centre, ERN-EURO-NMD, Avenida de Fernando Abril Martorell 106, 46026, Valencia, Spain.

Background: Distal myopathies (MPDs) are heterogeneous diseases of complex diagnosis whose prevalence and distribution in specific populations are unknown.

Methods: Demographic, clinical, genetic, neurophysiological, histopathological and muscle imaging characteristics of a MPDs cohort from a neuromuscular reference center were analyzed to study their epidemiology, features, genetic distribution and factors related to diagnosis.

Results: The series included 219 patients (61% were men, 94% Spanish and 41% sporadic cases).

View Article and Find Full Text PDF

[Aceneuraminic acid for distal myopathy].

Nihon Yakurigaku Zasshi

January 2025

Department of Neurology, Tohoku University School of Medicine.

Distal myopathy with rimmed vacuoles (GNE myopathy) is an incurable disease that develops after the late teens, progresses slowly, and has no effective treatment. It is inherited in an autosomal recessive manner, and the number of patients in Japan is estimated to be around 400. The causative gene was revealed to be GNE, the rate-limiting enzyme in the sialic acid biosynthesis pathway, and non-clinical studies demonstrated the effectiveness of sialic acid.

View Article and Find Full Text PDF

Introduction: GNE-myopathy is a distal myopathy with adult-onset and initial involvement of anterior leg compartment. A founder effect has been demonstrated for some patients from several large cohorts in different countries.

Methods: In this study, we investigated the allele frequency of the c.

View Article and Find Full Text PDF

Rare genetic disorders are low in prevalence and hence there is little or no attention paid to them in the mainstream medical industry. One of the ultra-rare neuromuscular disorders, GNE myopathy is caused due to biallelic mutations in the bifunctional enzyme, GNE (UDP N-acetylglucosamine-2-epimerase/N-acetylmannosamine kinase). It catalyses the rate-limiting step in sialic acid biosynthesis.

View Article and Find Full Text PDF

A pilot trial for efficacy confirmation of 6'-sialyllactose supplementation in GNE myopathy: Randomized, placebo-controlled trial.

Mol Genet Metab

January 2025

Department of Neurology, Pusan National University School of Medicine, Busan, Republic of Korea; Department of Neurology and Biomedical Research institute, Pusan National University Yangsan Hospital, Gyeongsangnam-do, Republic of Korea. Electronic address:

Article Synopsis
  • GNE myopathy is a rare genetic muscle disorder that leads to weakness in the ankles and muscle degeneration, caused by mutations in the GNE gene that reduce sialic acid production.
  • A clinical trial tested a supplement, 6'-sialyllactose (6SL), at doses of 3g and 6g to see if it could improve muscle strength and health, revealing better outcomes in muscle strength and reduced degeneration with the higher dose.
  • The latest study involved 11 participants to compare 6SL with a placebo group over 48 weeks, finding no major differences in muscle strength but a significant degeneration in muscle fat measured by MRI, indicating muscle health issues, particularly in the placebo group.
View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!